Welcome to our dedicated page for G1 Therapeutics news (Ticker: $GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect G1 Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of G1 Therapeutics's position in the market.
G1 Therapeutics announced Phase 2 trial results showing that trilaciclib, combined with sacituzumab govitecan (SG), extends overall survival (OS) in metastatic triple-negative breast cancer (mTNBC) patients compared to SG alone.
Key findings include a median OS improvement to 15.9 months in the intent-to-treat (ITT) population and up to 17.9 months in a more comparable patient population. Trilaciclib also reduced multiple adverse events like neutropenia, anemia, and diarrhea.
The results will be presented at the 2024 ASCO meeting and support further evaluation in combination trials.
G1 Therapeutics (Nasdaq: GTHX) announced the upcoming presentation of mature Phase 2 results on trilaciclib combined with sacituzumab govitecan (SG) at the ASCO 2024 Meeting from May 31 to June 4 in Chicago. The data indicates a positive impact on overall survival (OS) and tolerability in metastatic triple-negative breast cancer (mTNBC) compared to SG alone. The poster session detailing these findings will occur on June 2, 2024, from 9:00 AM to 12:00 PM CDT.
The abstract includes initial trial results shared in January 2024, with the new poster providing updated Phase 2 safety and efficacy outcomes.
G1 Therapeutics (Nasdaq: GTHX), a commercial-stage oncology company, announced that its Chief Medical Officer, Dr. Raj Malik, and Chief Commercial Officer, Andrew Perry, will participate in TD Cowen’s 5th Annual Oncology Innovation Summit.
The event will take place on May 29, 2024, at 8:30 AM EDT. A webcast of the fireside chat will be available on the company's Events & Presentations page.
G1 Therapeutics (Nasdaq: GTHX) and Deimos Biosciences, a Jupiter Bioventures portfolio company, announced a global licensing agreement for lerociclib, excluding the Asia-Pacific region. Lerociclib, a potent CDK4/6 inhibitor, will be developed for radioprotective uses. Jupiter Bioventures gains exclusive rights for clinical development, regulatory submissions, and commercialization in the US, Europe, Japan, and other markets excluding Asia-Pacific. G1 will receive 10% of Deimos' common stock and 20% royalties on annual net sales. The agreement aims to advance a solution in a high unmet need area.
G1 Therapeutics, Inc. announced the grant of inducement stock options and restricted stock units to a newly hired employee under the Amended and Restated 2021 Plan. The stock options are exercisable for 2,100 shares at $4.13 per share, with a ten-year term and vesting over four years. The RSUs consist of 1,050 units, vesting over four years as well. These awards were granted to induce the new employee to join G1 as per Nasdaq rules.
G1 Therapeutics reported $14.1 million in net revenue from sales of COSELA for Q1 2024, reaffirming $60-$70 million guidance for 2024. They announced updated efficacy results and final analysis from key trials. Cash runway extends to Q3 2025.
The financial results for Q1 2024 showed total revenue of $14.5 million, including $14.1 million from COSELA sales. Operating expenses decreased compared to Q1 2023. G1 reaffirmed its 2024 financial guidance of $60-$70 million in COSELA net revenue.
G1 Therapeutics, Inc. and Pepper Bio have announced a global licensing agreement for lerociclib, excluding Asia-Pacific, where Pepper Bio gains exclusive rights for clinical development, regulatory submissions, and commercialization in the US, Europe, Japan, and other global markets. Lerociclib, a selective CDK4/6 inhibitor, has shown promising efficacy in clinical studies, particularly in HR+/Her2- metastatic breast cancer and hepatocellular carcinoma. Pepper Bio's COMPASS platform identifies novel drug targets and will advance lerociclib to Phase 2 trials. G1 Therapeutics will receive mid-single-digit millions upfront and up to $135M in milestone payments, along with double-digit royalties on lerociclib sales.
